Cargando…

Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome

Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in...

Descripción completa

Detalles Bibliográficos
Autores principales: Leshem, Avner, Horesh, Nir, Elinav, Eran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587678/
https://www.ncbi.nlm.nih.gov/pubmed/31258528
http://dx.doi.org/10.3389/fimmu.2019.01341
_version_ 1783429117371219968
author Leshem, Avner
Horesh, Nir
Elinav, Eran
author_facet Leshem, Avner
Horesh, Nir
Elinav, Eran
author_sort Leshem, Avner
collection PubMed
description Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in recent years to be altered in patients suffering from features of cardiometabolic syndrome and to transmit cardiometabolic phenotypes upon transfer into germ-free mice. As a result, there is great interest in developing new modalities targeting the altered commensal bacteria as a means of treatment for cardiometabolic syndrome. Fecal microbiota transplantation (FMT) is one such modality in which a disease-associated microbiome is replaced by a healthy microbiome configuration. So far clinical use of FMT has been overwhelmingly successful in recurrent Clostridium difficile infection and is being extensively studied in other microbiome-associated pathologies such as cardiometabolic syndrome. This review will focus on the rationale, promises and challenges in FMT utilization in human disease. In particular, it will overview the role of the gut microbiota in cardiometabolic syndrome and the rationale, experience, and prospects of utilizing FMT treatment as a potential preventive and curative treatment of metabolic human disease.
format Online
Article
Text
id pubmed-6587678
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65876782019-06-28 Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome Leshem, Avner Horesh, Nir Elinav, Eran Front Immunol Immunology Newly revealed links between inflammation, obesity, and cardiometabolic syndrome have created opportunities to try previously unexplored therapeutic modalities in these common and life-risking disorders. One potential modulator of these complex disorders is the gut microbiome, which was described in recent years to be altered in patients suffering from features of cardiometabolic syndrome and to transmit cardiometabolic phenotypes upon transfer into germ-free mice. As a result, there is great interest in developing new modalities targeting the altered commensal bacteria as a means of treatment for cardiometabolic syndrome. Fecal microbiota transplantation (FMT) is one such modality in which a disease-associated microbiome is replaced by a healthy microbiome configuration. So far clinical use of FMT has been overwhelmingly successful in recurrent Clostridium difficile infection and is being extensively studied in other microbiome-associated pathologies such as cardiometabolic syndrome. This review will focus on the rationale, promises and challenges in FMT utilization in human disease. In particular, it will overview the role of the gut microbiota in cardiometabolic syndrome and the rationale, experience, and prospects of utilizing FMT treatment as a potential preventive and curative treatment of metabolic human disease. Frontiers Media S.A. 2019-06-14 /pmc/articles/PMC6587678/ /pubmed/31258528 http://dx.doi.org/10.3389/fimmu.2019.01341 Text en Copyright © 2019 Leshem, Horesh and Elinav. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Leshem, Avner
Horesh, Nir
Elinav, Eran
Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title_full Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title_fullStr Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title_full_unstemmed Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title_short Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
title_sort fecal microbial transplantation and its potential application in cardiometabolic syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587678/
https://www.ncbi.nlm.nih.gov/pubmed/31258528
http://dx.doi.org/10.3389/fimmu.2019.01341
work_keys_str_mv AT leshemavner fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome
AT horeshnir fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome
AT elinaveran fecalmicrobialtransplantationanditspotentialapplicationincardiometabolicsyndrome